scholarly journals The Impact of Systemic Factors on Clinical Response to Ranibizumab for Diabetic Macular Edema

Ophthalmology ◽  
2016 ◽  
Vol 123 (7) ◽  
pp. 1581-1587 ◽  
Author(s):  
Rishi P. Singh ◽  
Karishma Habbu ◽  
Justis P. Ehlers ◽  
M. Cecilia Lansang ◽  
Lauren Hill ◽  
...  
Keyword(s):  
Macular Edema ◽  
Clinical Response ◽  
Diabetic Macular Edema ◽  
Systemic Factors ◽  
The Impact

The impact of metabolic parameters on clinical response to VEGF inhibitors for diabetic macular edema

2014 ◽  
Vol 28 (2) ◽  
pp. 166-170 ◽  
Author(s):  
Simone Matsuda ◽  
Tiffany Tam ◽  
Rishi P. Singh ◽  
Peter K. Kaiser ◽  
Dan Petkovsek ◽  
...  
Keyword(s):  
Macular Edema ◽  
Clinical Response ◽  
Diabetic Macular Edema ◽  
Metabolic Parameters ◽  
Vegf Inhibitors ◽  
The Impact

scholarly journals Systemic Factors Associated with Treatment Response in Diabetic Macular Edema

2020 ◽  
Vol 2020 ◽  
pp. 1-6 ◽  
Author(s):  
Wendy Meihua Wong ◽  
Caroline Chee ◽  
Mayuri Bhargava ◽  
Charmaine Chai ◽  
Hazel Lin ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Glycosylated Hemoglobin ◽  
Univariate Analysis ◽  
Macular Thickness ◽  
Spectral Domain ◽  
Anti Vegf ◽  
Systemic Factors ◽  
Nonnormal Distribution

Purpose. To identify systemic factors that may influence the response to anti-VEGF therapy in patients with diabetic macular edema (DME). Methods. 35 patients undergoing anti-VEGF injections for centre-involving DME were studied in this prospective observational study. The primary outcome was change in macular thickness one month after treatment, measured using spectral-domain optical coherence tomography (OCT). At baseline, information on various systemic factors was collected including glycosylated hemoglobin (HbA1c), serum VEGF levels, lipid profile and markers of renal function, and blood pressure. Thirty-three of the 35 patients were included in this study. Nonparametric statistical tests were used for the analysis of the data in view of the nonnormal distribution of the outcome variables. Multivariate analysis was performed using logistic regression. Stata 12.1 software was used for the analysis. Main Outcome Measures. Reduction in macular central subfield thickness (on spectral-domain OCT) and change in logMAR visual acuity at one month after injection. Results. Lower HbA1c levels (7% or less) were significantly associated with greater reduction in central macular subfield thickness at one month after injection of bevacizumab or ranibizumab on both univariate analysis (p=0.012) and multivariate analysis (p=0.042). Conclusions. Better glycemic control is associated with a greater reduction in central macular thickness after the first injection of bevacizumab or ranibizumab in diabetic macular edema. Patients with high levels of HbA1c and poor response to anti-VEGF may benefit from strict control of their blood glucose.

scholarly journals The Impact of Interval between Recurrence and Reinjection in Anti-VEGF Therapy for Diabetic Macular Edema in Pro Re Nata Regimen

2021 ◽  
Vol 10 (24) ◽  
pp. 5738
Author(s):  
Yoshihiro Takamura ◽  
Teruyo Kida ◽  
Hidetaka Noma ◽  
Makoto Inoue ◽  
Shigeo Yoshida ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Functional Improvement ◽  
Vascular Endothelial ◽  
Anti Vegf ◽  
Group 3 ◽  
Pro Re Nata ◽  
Endothelial Growth Factor ◽  
The Impact ◽  
Deferred Group

Background: Pro re nata (PRN) regimen using anti-vascular endothelial growth factor (VEGF) agent is popular for the treatment of diabetic macular edema (DME). We investigated the influence of waiting time (WT) and interval between the date of recurrence of edema and re-injection on treatment efficacy. Methods: This retrospective study conducted at 7 sites in Japan enrolled patients who received intravitreal injection of ranibizumab (IVR) and aflibercept (IVA) in 1+PRN regimen. Enrolled patients were divided into 2 groups: prompt group (less than 1 week) and deferred group (3 weeks or more). Central retinal thickness (CRT) and best corrected visual acuity (BCVA) were measured every month for 1 year. Results: CRT in the deferred group was significantly higher than that in the prompt group at 2, 5, 6, 7, and 12 months (p < 0.05). BCVA in the prompt group was significantly better than that in the deferred group at 7, 10, and 12 months (p < 0.05). Conclusion: The prompt group was superior in anatomical and functional improvement of DME in anti-VEGF therapy than the deferred group. Our data suggests that shorter WT is recommended for better visual prognosis in the treatment for DME.

scholarly journals The Impact of Aflibercept on Diabetic Macular Edema Patients Refractory to Ranibizumab in a Tertiary Care Eye Specialist Hospital, Saudi Arabia

2021 ◽  
Vol 7 (3) ◽  
pp. 82-85
Author(s):  
Abdullah AlHumaidan ◽  
Sitah AlZuman ◽  
Muhammad Haris Mazhar ◽  
Arwa A AlDahash ◽  
Wejdan AlMussalam ◽  
...  
Keyword(s):  
Saudi Arabia ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Tertiary Care ◽  
The Impact

scholarly journals Identifying Genetic Risk Factors for Diabetic Macular Edema and the Response to Treatment

2020 ◽  
Vol 2020 ◽  
pp. 1-12
Author(s):  
Rajya L. Gurung ◽  
Liesel M. FitzGerald ◽  
Bennet J. McComish ◽  
Nitin Verma ◽  
Kathryn P. Burdon
Keyword(s):  
Risk Factors ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Genetic Risk ◽  
Vision Loss ◽  
Genetic Risk Factors ◽  
Response To Treatment ◽  
Diabetic Eye Disease ◽  
Genetic And Environmental Factors ◽  
The Impact

Diabetic retinopathy (DR) is the most common microvascular complication of diabetes mellitus (DM). DR is complex and the term encompasses several clinical subtypes of diabetic eye disease, including diabetic macular edema (DME), the most frequent cause of central vision loss in DR patients. Both genetic and environmental factors contribute to the pathophysiology of DR and its subtypes. While numerous studies have identified several susceptibility genes for DR, few have investigated the impact of genetics on DME susceptibility. This review will focus on the current literature surrounding genetic risk factors associated with DME. We will also highlight the small number of studies investigating the genetics of response to antivascular endothelial growth factor (anti-VEGF) injection, which is used to treat DME.

Sign in / Sign up

Export Citation Format

Share Document